Ascendis Pharma to present new data on rare endocrine disease treatments at ENDO 2026 conference.

Ascendis Pharma announced it will share new clinical trial data on treatments for rare endocrine diseases including hypoparathyroidism, achondroplasia, and pediatric growth hormone deficiency at the ENDO 2026 conference in Chicago. The presentations will highlight the long-term safety and efficacy of their TransCon therapies, such as TransCon PTH and TransCon CNP, demonstrating potential improvements in patient outcomes. This event underscores Ascendis' commitment to advancing innovative therapies for rare conditions and may influence future treatment approaches. The data presentations are scheduled from June 13-16, 2026.